Neuroplasticity in Parkinson's disease.

Publisher: Springer-Verlag Country of Publication: Austria NLM ID: 9702341 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-1463 (Electronic) Linking ISSN: 03009564 NLM ISO Abbreviation: J Neural Transm (Vienna) Subsets: MEDLINE

Original Publication: Wien ; New York : Springer-Verlag, 1996-

Neuronal Plasticity*/physiology ; Parkinson Disease*/physiopathology ; Parkinson Disease*/metabolism ; Parkinson Disease*/pathology ; Parkinson Disease*/therapy; Humans ; Animals ; Brain/physiopathology ; Brain/metabolism ; Brain/pathology

Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, affecting millions of people and rapidly increasing over the last decades. Even though there is no intervention yet to stop the neurodegenerative pathology, many efficient treatment methods are available, including for patients with advanced PD. Neuroplasticity is a fundamental property of the human brain to adapt both to external changes and internal insults and pathological processes. In this paper we examine the current knowledge and concepts concerning changes at network level, cellular level and molecular level as parts of the neuroplastic response to protein aggregation pathology, synapse loss and neuronal loss in PD. We analyse the beneficial, compensatory effects, such as augmentation of nigral neurons efficacy, as well as negative, maladaptive effects, such as levodopa-induced dyskinesia. Effects of physical activity and different treatments on neuroplasticity are considered and the opportunity of biomarkers identification and use is discussed.
(© 2024. The Author(s).)

Adv Physiol Educ. 2014 Jun;38(2):109-17. (PMID: 25039081)
N Engl J Med. 1998 Oct 8;339(15):1044-53. (PMID: 9761807)
Neural Plast. 2020 Dec 14;2020:8856621. (PMID: 33414823)
Rev Neurosci. 2021 Aug 30;33(2):213-226. (PMID: 34461010)
Front Neurol. 2022 Jul 14;13:938686. (PMID: 35911891)
J Neurol. 2002 Oct;249 Suppl 3:III/1-5. (PMID: 12528692)
Physiol Rev. 2023 Oct 1;103(4):2877-2925. (PMID: 37290118)
Neurobiol Dis. 2022 Jun 1;167:105674. (PMID: 35245676)
Parkinsonism Relat Disord. 2023 Dec;117:105908. (PMID: 37922635)
J Parkinsons Dis. 2024;14(2):261-267. (PMID: 38339940)
Neuroscientist. 2016 Aug;22(4):359-71. (PMID: 25993993)
Curr Opin Neurobiol. 2005 Apr;15(2):161-7. (PMID: 15831397)
Nat Rev Neurosci. 2010 Dec;11(12):799-811. (PMID: 21045861)
J Physiol Pharmacol. 2014 Jun;65(3):441-8. (PMID: 24930517)
Seizure. 1996 Sep;5(3):185-94. (PMID: 8902919)
Neuron. 2015 Jan 21;85(2):364-76. (PMID: 25578364)
Prog Neurobiol. 1990;34(3):197-269. (PMID: 2157237)
Ann Neurol. 2017 Jul;82(1):4-19. (PMID: 28543679)
Mayo Clin Proc. 2018 Mar;93(3):360-372. (PMID: 29502566)
J Neurochem. 2016 Oct;139 Suppl 1:338-345. (PMID: 27273305)
Int J Mol Sci. 2021 May 18;22(10):. (PMID: 34070217)
J Neurol Neurosurg Psychiatry. 2010 May;81(5):536-8. (PMID: 20176597)
Neurobiol Dis. 2023 Jan;176:105945. (PMID: 36481436)
Front Neurosci. 2023 Sep 29;17:1296291. (PMID: 37841683)
Mov Disord. 2020 Sep;35(9):1607-1617. (PMID: 32557868)
Exp Gerontol. 2017 Mar;89:20-29. (PMID: 28062370)
Neurosci Res. 2002 Jun;43(2):111-7. (PMID: 12067746)
Hum Neurobiol. 1984;2(4):235-44. (PMID: 6715208)
Exp Neurol. 2021 Aug;342:113741. (PMID: 33965411)
Prog Neurobiol. 2024 Jan;232:102548. (PMID: 38040324)
Pharmacol Ther. 2024 Mar;255:108606. (PMID: 38346477)
Trends Neurosci. 2023 Jul;46(7):566-580. (PMID: 37202300)
J Neurosci. 2020 Sep 23;40(39):7451-7463. (PMID: 32847963)
Lancet. 2024 Jan 20;403(10423):305-324. (PMID: 38245250)
Neurosci Biobehav Rev. 2021 Sep;128:394-405. (PMID: 34087277)
Ageing Res Rev. 2022 Feb;74:101543. (PMID: 34923167)
Neurobiol Dis. 2020 Feb;134:104671. (PMID: 31706021)
Brain Stimul. 2018 Sep - Oct;11(5):1140-1150. (PMID: 29779963)
Function (Oxf). 2023 Oct 03;4(6):zqad056. (PMID: 37841525)
J Neurol. 2017 Jan;264(1):88-101. (PMID: 27778161)
Oral Dis. 2016 Nov;22(8):745-753. (PMID: 26878123)
Neurology. 2022 Feb 22;98(8):e859-e871. (PMID: 35022304)
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S237-40. (PMID: 20082999)
Neurosci Biobehav Rev. 2013 Nov;37(9 Pt A):2071-80. (PMID: 23567518)
CNS Drugs. 2012 Dec;26(12):1017-32. (PMID: 23114872)
Philos Trans R Soc Lond B Biol Sci. 2017 Mar 5;372(1715):. (PMID: 28093558)
Curr Opin Neurobiol. 2024 Apr;85:102839. (PMID: 38309106)
Trends Neurosci. 1994 May;17(5):190-2. (PMID: 7520199)
Sci Adv. 2023 Jul 14;9(28):eadh1403. (PMID: 37450585)
Neurology. 2017 Oct 24;89(17):1804-1810. (PMID: 28954877)
Arch Phys Med Rehabil. 2008 Jul;89(7):1221-9. (PMID: 18534554)
Neurology. 1994 Mar;44(3 Pt 1):376-8. (PMID: 8145901)
Front Psychol. 2022 Apr 26;13:831819. (PMID: 35558719)
BMC Neurol. 2011 Jun 23;11:75. (PMID: 21699711)
Brain Sci. 2024 Feb 21;14(3):. (PMID: 38539583)
Ageing Res Rev. 2022 Sep;80:101698. (PMID: 35853549)
Cold Spring Harb Symp Quant Biol. 1990;55:175-86. (PMID: 1983443)
Front Netw Physiol. 2022 Mar 04;2:817524. (PMID: 36926058)
Ageing Res Rev. 2023 Dec;92:102089. (PMID: 37844764)
Neurorehabil Neural Repair. 2015 Jul;29(6):577-89. (PMID: 25527485)
Mov Disord. 2023 Mar;38(3):410-422. (PMID: 36656044)
Int J Mol Sci. 2023 Apr 28;24(9):. (PMID: 37175699)
Appl Neurophysiol. 1987;50(1-6):344-6. (PMID: 3329873)
Neural Plast. 2020 Mar 5;2020:8961493. (PMID: 32256559)
Neuropharmacology. 2010 Jun;58(7):951-61. (PMID: 20096294)
J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):549-50. (PMID: 10201440)
Life Sci. 2012 Dec 17;91(25-26):1309-16. (PMID: 23069581)
Brain. 2018 Jan 1;141(1):177-190. (PMID: 29236966)
Heliyon. 2024 May 07;10(10):e30730. (PMID: 38784548)
Mov Disord. 2019 Dec;34(12):1891-1900. (PMID: 31584222)
Neuropharmacology. 2024 Oct 1;257:110036. (PMID: 38876308)
Front Physiol. 2024 Feb 20;15:1352305. (PMID: 38444767)
Eur J Neurosci. 2018 Sep;48(5):2139-2151. (PMID: 30103273)
Philos Trans R Soc Lond B Biol Sci. 1990 Aug 29;329(1253):187-204. (PMID: 1978364)
Nat Rev Neurosci. 2013 Jan;14(1):7-23. (PMID: 23254191)
Exp Gerontol. 2021 Jul 15;150:111384. (PMID: 33965556)
Neuron. 2017 Sep 13;95(6):1306-1318.e5. (PMID: 28910619)
Sci Rep. 2017 Jan 27;7:41432. (PMID: 28128287)
Neurobiol Aging. 2014 Jan;35(1):232-9. (PMID: 23916062)
Curr Opin Neurobiol. 2023 Dec;83:102781. (PMID: 37696188)
Neurobiol Dis. 2022 Jun 1;167:105686. (PMID: 35272023)
Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S25-9. (PMID: 15885624)
Neuroreport. 2013 Jul 10;24(10):509-14. (PMID: 23636255)
Curr Opin Neurobiol. 2015 Aug;33:188-96. (PMID: 26189204)
Philos Trans R Soc Lond B Biol Sci. 2013 Dec 02;369(1633):20130131. (PMID: 24298134)
Brain Sci. 2022 Jul 15;12(7):. (PMID: 35884734)
J Clin Med. 2020 Jan 09;9(1):. (PMID: 31936624)
Cell Mol Neurobiol. 2018 Apr;38(3):579-593. (PMID: 28623429)
Neuron. 2003 Sep 11;39(6):889-909. (PMID: 12971891)
Neurology. 2011 Jul 19;77(3):288-94. (PMID: 21768599)
Neurobiol Dis. 2022 May;166:105650. (PMID: 35139431)
Cell Rep. 2015 Aug 11;12(6):944-54. (PMID: 26235617)
Brain Plast. 2022 Oct 21;8(1):121-128. (PMID: 36448042)
Ann Neurol. 2010 Jun;67(6):715-25. (PMID: 20517933)
Neuroreport. 2023 Jun 7;34(10):506-511. (PMID: 37270842)
Brain Commun. 2024 Mar 28;6(3):fcae093. (PMID: 38707711)
Neuron. 2018 Oct 24;100(2):314-329. (PMID: 30359599)
Eur J Neurosci. 2024 Mar;59(6):1227-1241. (PMID: 37876330)
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S78-81. (PMID: 26439945)
Neurology. 2010 Jul 27;75(4):341-8. (PMID: 20660864)
Eur J Neurosci. 2022 Aug;56(3):4187-4213. (PMID: 35724981)
Neuroscience. 2013 May 1;237:118-29. (PMID: 23396085)

1N/2023/ PN 23.16.01.02 Ministerul Cercetării şi Inovării

Keywords: AMPA; BDNF; Biomarkers; Dopamine; NMDA; Neuroplasticity; Parkinson’s disease

Date Created: 20240805 Date Completed: 20241024 Latest Revision: 20241027

20241027

PMC11502561

10.1007/s00702-024-02813-y

39102007